Session: MON 37-82-Pheochromocytoma & Paraganglioma
Poster Board MON-57
Purpose: In the present study we included 106 patients with SDHB-related PHEOs/PGLs in order to evaluate relationship in between the size of the primary tumor, patient survival and tumor metastatic potential taking into account SDHB specific mutation type.
Methods: In this retrospective study we determined the largest diameter of the primary tumor in 106 patients with SDHB mutations and analyzed this data in the context of their size, survival time, type of tumor, time to metastasis and hazard ratio.
Results: Our survival curves indicated that the patients with primary tumors 5.5 cm or larger have a worse overall survival (P=0.0028), with a 5-year survival probability
of 86.7% compared to 96.2% for patients diagnosed with tumors smaller then 5.5 cm. Although patients with tumors 4.5 cm or larger only have synchronous metastases at a slightly higher rate (29.6% vs 20.0%, P=0.35), overall they develop metastases much faster (P=0.0025) than patients with tumors smaller than 4.5 cm.
Conclusion: Size of the primary tumor has been confirmed to be an important predictor of metastatic potential and survival rate, independently of the specific SDHB mutation and sex of the patient. This should be projected into the clinical practice as recommendation for implementing the latest imaging technologies and guidelines.
Nothing to Disclose: JS, VLM, TF, RW, JD, TH, KTA, ZF, KP
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters